Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression
L Roseman, DJ Nutt, RL Carhart-Harris - Frontiers in Pharmacology, 2018 - frontiersin.org
Patients' accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression
R Watts, C Day, J Krzanowski, D Nutt… - Journal of …, 2017 - journals.sagepub.com
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
L Roseman, L Demetriou, MB Wall, DJ Nutt… - …, 2018 - Elsevier
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
L Roseman, R Leech, A Feilding, DJ Nutt… - Frontiers in human …, 2014 - frontiersin.org
A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment
S Turton, DJ Nutt… - Current Drug Abuse …, 2014 - ingentaconnect.com
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future
D Nutt - 2016 - journals.sagepub.com
Question-based Drug Development for psilocybin–Authors' reply
RL Carhart-Harris, DJ Nutt - The Lancet Psychiatry, 2016 - thelancet.com
A review of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy
B Sessa, L Higbed, D Nutt - Frontiers in Psychiatry, 2019 - frontiersin.org
MDMA, politics and medical research: Have we thrown the baby out with the bathwater?
B Sessa, DJ Nutt - 2007 - journals.sagepub.com
The current status of psychedelics in psychiatry
D Nutt, R Carhart-Harris - JAMA psychiatry, 2021 - jamanetwork.com